Kane Biotech Provides Additional Information Regarding Engagement of Investor Relations Counsel

WINNIPEG, Manitoba, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce additional information regarding its engagement of Edison Advisors (“Edison”) as the Corporation’s investor relations counsel. The following disclosure supplements the information contained in the Corporation’s press release from earlier today.

Edison’s North American operations are headquartered in New York, New York. Edison’s global head office is in London, United Kingdom. Neither Edison nor any of its employees has any direct or indirect ownership interest in Kane Biotech. Kane Biotech has engaged Edison as its investor relations counsel for a period of one year from the date hereof. Kane Biotech has agreed to pay Edison US$8,000 per month for the investor relations services detailed in Kane Biotech’s prior press release. The total cost to Kane Biotech for the one year engagement of Edison is US$96,000. The funds used to pay Edison will come from Kane Biotech’s available working capital.

The engagement of Edison as Kane Biotech’s investor relations counsel remains subject to the final approval of the TSX Venture Exchange.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

The Corporation has a portfolio of biotechnologies, intellectual property (76 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc.   The Corporation is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.

For more information, please visit www.kanebiotech.com or contact:

Mark Ahrens-Townsend
President & CEO, Kane Biotech Inc.                                              
ir@kanebiotech.com
+1 (204) 477-7592

Tirth Patel
Edison Advisors
Investor Relations
tpatel@edisongroup.com
+1 (646) 653-7035

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Released February 1, 2018